Capricor Therapeutics lost $42.7 million last quarter and talked about its treatment for Duchenne muscular dystrophy.

Nov 10, 2026, 5:19 PM ETTrialRead the original at Benzinga

Good for CAPR

Capricor reported a $42.7 million Q3 loss and had $198.5 million in cash, with FDA review still ongoing. Its 1.1-point HOPE-3 result strengthens its drug case, though approval is pending and a distribution-rights dispute continues.

CAPR · Capricor Therapeutics

AI read · Good for CAPR

The AI's read

That result gives regulators a clear measure of how the drug affected arm and hand function. Capricor also has $198.5 million in cash as it prepares for a launch, but reported a $42.7 million quarterly loss. FDA approval is still pending, and the NS Pharma distribution dispute remains unresolved.

Get alerts for CAPR

Follow Capricor Therapeutics (CAPR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CAPR

Free on the App Store and Google Play, or on the web.